Leerink Partnrs Reaffirms “Outperform” Rating for AnaptysBio (NASDAQ:ANAB)

Leerink Partnrs reaffirmed their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note issued to investors on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for AnaptysBio’s Q1 2024 earnings at ($1.41) EPS, Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, FY2024 earnings at ($5.71) EPS, Q1 2025 earnings at ($1.91) EPS, Q2 2025 earnings at ($1.86) EPS, Q3 2025 earnings at ($1.85) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($6.37) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at ($3.95) EPS and FY2028 earnings at ($3.39) EPS.

Several other equities research analysts have also commented on ANAB. Piper Sandler assumed coverage on AnaptysBio in a research note on Friday, February 16th. They set an overweight rating and a $80.00 price target for the company. BTIG Research began coverage on AnaptysBio in a research note on Monday, February 26th. They issued a buy rating and a $55.00 target price for the company. Wedbush upgraded AnaptysBio from a neutral rating to an outperform rating and increased their target price for the company from $20.00 to $34.00 in a research note on Tuesday, March 12th. SVB Leerink began coverage on AnaptysBio in a research note on Tuesday. They issued an outperform rating and a $47.00 target price for the company. Finally, Wells Fargo & Company began coverage on AnaptysBio in a research note on Thursday, April 11th. They issued an overweight rating and a $56.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $46.22.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB opened at $19.83 on Tuesday. The firm has a market capitalization of $530.65 million, a PE ratio of -3.26 and a beta of -0.30. The business has a 50-day moving average of $23.31 and a two-hundred day moving average of $20.54. AnaptysBio has a 12 month low of $13.36 and a 12 month high of $27.50.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) EPS for the quarter, topping the consensus estimate of ($1.74) by $0.15. The company had revenue of $9.01 million during the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. As a group, research analysts anticipate that AnaptysBio will post -6.25 earnings per share for the current year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, CEO Daniel Faga sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the sale, the chief executive officer now owns 749,087 shares in the company, valued at approximately $16,045,443.54. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other AnaptysBio news, CEO Daniel Faga sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the sale, the chief executive officer now owns 749,087 shares in the company, valued at approximately $16,045,443.54. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Eric J. Loumeau sold 5,000 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the transaction, the insider now directly owns 3,240 shares in the company, valued at approximately $81,000. The disclosure for this sale can be found here. Insiders sold a total of 157,005 shares of company stock worth $3,586,199 in the last 90 days. 35.50% of the stock is owned by corporate insiders.

Institutional Trading of AnaptysBio

Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its holdings in shares of AnaptysBio by 2.1% in the 1st quarter. BlackRock Inc. now owns 1,895,494 shares of the biotechnology company’s stock worth $41,246,000 after purchasing an additional 39,228 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of AnaptysBio by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,745,108 shares of the biotechnology company’s stock worth $44,518,000 after purchasing an additional 14,638 shares during the last quarter. State Street Corp lifted its holdings in shares of AnaptysBio by 10.0% in the 3rd quarter. State Street Corp now owns 1,271,727 shares of the biotechnology company’s stock worth $32,442,000 after purchasing an additional 115,846 shares during the last quarter. First Light Asset Management LLC lifted its holdings in shares of AnaptysBio by 56.4% in the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after purchasing an additional 446,372 shares during the last quarter. Finally, Woodline Partners LP lifted its holdings in shares of AnaptysBio by 125.1% in the 2nd quarter. Woodline Partners LP now owns 1,034,549 shares of the biotechnology company’s stock worth $21,043,000 after purchasing an additional 574,987 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.